XNAS · NVCT
+2.90% · +$0.6200 · Vol 880.1K
Market closed · last close 4:00 PM ET · price as of 16:15:21 ET
Nuvectis Pharma, Inc. Common Stock

Nuvectis Pharma, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$22.00
Card
Relationship Map

Follow $NVCT

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $NVCT by email

Veridion Score

BETALOW CONF · 6 of 6 factors measuredMethodology
NVCT
Nuvectis Pharma, Inc. Common Stock
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

42/ 100
Veridion Score
Lower range · LOW confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is NVCT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading NVCT catalysts
About Nuvectis Pharma, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2022
Employees
13
Country
US

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$21.27
Day high
$23.00
Day low
$21.06
Previous close
$21.38
52W high
$28.53
-22.89% from high
52W low
$5.65
71% of range
Market cap
$718.2M
EPS
$-1.3000
Beta
-0.05
Shares out
32.6M
Volume
880.1K
4.18× rel vol
Avg volume
210.4K
VWAP
$22.00
Price history computed in-house
1W
-8.30%
1M
-6.62%
3M
+33.09%
1Y
+250.88%
YTD
+191.39%
SMA 50 $21.27 · above
SMA 200 $12.75 · above
52W position 71%

NVCT overview

Veridion Score
42
Registered · 2026-09-18
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around NVCT.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading NVCT Form 4 filings
Public disclosures

Congress activity in NVCT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for NVCT in the cached public ledger.

Federal contracts

NVCT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NVCT in this window.
Lobbying spend

NVCT lobbying filings, year to date.

Registered lobbying filings matched to Nuvectis Pharma, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NVCT in this window.
Loading news for NVCT
Analyst ratings
Sovereign unlock shows live analyst consensus for NVCT.
Options
Sovereign unlock shows live options positioning for NVCT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.